ENGN
ENGN
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
2
$5.01M
Insider Sales
0
$0
Total Volume
$5.01M
2 transactions
Net Activity
+$5.01M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
- •Minor cluster buying: 2 unique insiders purchased shares.
- •High accumulation: total purchase value exceeds $1M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Forbion Growth Opportunities Fund I Cooperatief U.A.
10%
$5.00M total
Grossman William
Interim Chief Medical Officer
$10K total
Quick Actions
ENGN has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at ENGN (ENGN) engaged in a total of 2 transactions reported via SEC Form 4 filings. Among these, 2 were open-market purchases and 0 were sales. The total volume of insider trading reached $5.01M.
The net insider activity for ENGN shows a net buying bias of $5.01M. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Forbion Growth Opportunities Fund I Cooperatief U.A. (10%), who traded 561.8K shares valued at $5.00M on Oct 30, 2024.
EnGene Therapeutics (ENGN) Stock Gets Fair Value Boost After Analyst Views On LEGEND Data
StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer Therapy
ENGN: Detalimogene advances toward a 2027 approval, with a surfactant-cohort update planned for midyear
enGene rises after mid-stage trial data for bladder cancer therapy; Piper upgrades
ENGN - enGene Therapeutics Inc Stock Price and Quote
Warrants at $0.0001 a share factor into a fund's reported enGene Therapeutics (ENGN) stake.
FAQs About ENGN Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ENGN.